Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxyurea mechanisms of action on leukocyte activation in chronic myeloproliferative syndromes
2009-012784-34Phase 4Completed
- Sponsor
- Policlinico Gemelli
- Start
- Jun 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of hydroxyurea in myeloproliferative disorder (MPD) (2 arms), sponsored by Policlinico Gemelli. Primary endpoints: Nitric oxide production, cGMP production and 4 more. Started Jun 2009; status: completed.
02
Drugs
hydroxyurea
03
Conditions
myeloproliferative disorder (MPD)
Beyond the preview
Go deeper on 2009-012784-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012784-34.